UMB to refile $6.4B lawsuit against Bristol-Myers by end of next week - report
UMB Financial plans to refile a $6.4 billion lawsuit against Bristol-Myers Squibb over the acquisition of Celgene after a previous suit was dismissed.
The American Journal of Managed Care4h
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
Hosted on MSN6h
Bristol Myers Raises Profit Forecast on Drug Demand
(Bloomberg) -- Bristol Myers Squibb Co. raised its 2024 profit forecast as demand ... Bristol shares rose as much as 9.3% after US markets opened. The stock fell 12% this year through Thursday’s close ...
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
Alumis: Could This Broken Immunology IPO Become The Next Amgen?
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...
Zacks.com on MSN21h
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...
stocknews23h
3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...